Last news
VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma

VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma

...

COMPUTEX closed on a High Note

COMPUTEX closed on a High Note

...

UTS ranked in the top 20 universities globally for the second year in a row by an international index on sustainable development

UTS ranked in the top 20 universities globally for the second year in a row by an international index on sustainable development

...

Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives

Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives

...

Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting

...

Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting

Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting

...

Sanyou launches new European offices and continues to promote global business landscape

Sanyou launches new European offices and continues to promote global business landscape

...

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

...

1 ... 322 323 324 325 326 327 328 329 330 ... 1190
menu
menu